



Disparities in Treated Prevalence among Medicaid Beneficiaries with Mental Illnesses

Presenter Mihail Samnaliev, PhD

Funded by: RWJ Foundation Substance Abuse
Policy Research Program

Grant: “ Improving Treatment for Medicaid
Beneficiaries with Co-occurring
Disorders ”

PI: Robin Clark, PhD

Center for Health Policy & Research (chpr)
University of Massachusetts Medical School



Background

- **MI in Medicaid populations**
 - 43% of Medicaid beneficiaries have MI (Adelman 2003)
 - Medicaid MI expenditures = \$24 billion in 2001 (DHHS 2005)
- **Minorities are overrepresented in Medicaid**
 - 25% of African Americans have Medicaid
 - 22% of Hispanics have Medicaid
 - 9% of Whites have Medicaid



Background

- **Disparities documented in other populations**
 - A BCBS plan (Sheffler and Miller 1989)
 - 3 private insurance plans (Diehr et al 1984)
 - Separate Medicaid programs
- **Very few studies of Medicaid populations**
 - Most include one state or a MCO within state
 - Typically focus on pharmacological management

Objectives

- **All beneficiaries with MI expected to have equal Tx**
 - Same treatment within income and eligibility category
 - No theoretical reasons why MI Tx should differ by ethnicity/race
- **Does treated prevalence among Medicaid beneficiaries with MI differ by ethnicity?**
 - Are findings consistent across 6 diverse Medicaid populations?
 - Study separately community-based, ED and hospital settings
- **Significance of this study**
 - Greaten burden on individuals with MI and family members
 - Implications for Medicaid policy making

Populations

- 6 states from each region of the U.S:
Arkansas, Colorado, Georgia,
Indiana, New Jersey and Washington
- Medicaid programs differ substantially
Size, population mix, Eligibility criteria
Behavioral health care arrangements
- States differ substantially
Geographic location and demographics
Local economies, policies, supply of medical resources.

Methods

- Identify individuals with 12 month prevalence of MI
- Logistic regression to model Pr [MI treatment]
- Separate model by state and setting (18 models)
- Estimate effects of race/ethnicity

Results

- A total of 4 million beneficiaries
- 55% White, 6% Hispanic, 30% African American
- 350,000 (9%) diagnosed with MI
- 176,000 (50%) diagnosed with comorbidities
 - 5.2% had asthma, 12% had COPD
 - 14% had diabetes, 23% had hypertension
 - 12% had substance use disorders

Results

- Most had a disability (61% - 73%)
- Two thirds aged 21 to 44 (vs 44 to 65)
- FFS ranged from 7% to 91%
- 68% to 78% had continuous M-aid coverage
- Treatment
 - 32% to 72% were treated in community settings
 - 6% to 15% in ED
 - 2% to 14% in inpatient settings




Adjusted Odds Ratios

Settings	Community-based		Inpatient		Emergency department	
	Hispanic	African American	Hispanic	African American	Hispanic	African American
AR	.79 ^a	.89	.99	.94	1.23	1.55 ^c
CO	.80 ^c	.66 ^c	.58 ^b	1.06	1.07	1.00
GA	.67 ^b	.59 ^c	.72	1.21 ^b	0.65	1.22 ^c
IN	.44 ^c	.49 ^c	1.23	1.08	1.66 ^c	1.74 ^c
NJ	.88 ^c	.64 ^c	1.29 ^c	1.18 ^c	0.81 ^b	1.17 ^b
WA	.75 ^c	.63 ^c	.72 ^a	1.24 ^a	0.94	1.02

a = p<0.1; b=p<0.05; c=p<0.01 compared to White. Adjusting for age, gender, continuity of eligibility, eligibility category, severity of mental illness, co-occurring substance use disorders, physical comorbidities, and local economy variables

Probability of community-based treatment



Conclusions

- Lower rates of CAB MI treatment among African Americans and Hispanics
- Higher or similar rates of inpatient and ER Tx among African Americans
- Extends previous studies of single Medicaid programs
- Implications associated with greater burden of disease on ethnic minorities

Implications for Medicaid

- Medicaid coverage not sufficient by itself
- Future efforts for engagement in Tx should focus on interventions in the community
- Medicaid programs are well positioned to implement policies

Waivers, new benefits, financial incentives to consumers and providers, culturally sensitive treatment